PRNewsWire
02 Aug 2026, 15:13 UTC · 3h ago
Mezzion Reports Positive In Vivo Results for Udenafil in ADPKD
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
PRNewsWire
02 Aug 2026, 15:13 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Mezzion Pharma reported positive in vivo results for udenafil in treating autosomal dominant polycystic kidney disease (ADPKD), showing statistically significant reductions in kidney cyst burden and blood urea nitrogen. — Positive preclinical data for a rare disease indication creates a new value driver and potential future revenue stream for the company.
+0.60Mezzion plans to advance udenafil into a Phase 2b clinical study in adults with rapidly progressing ADPKD. — Transitioning from preclinical to clinical stages increases the probability of regulatory success and validates the drug's potential.
+0.40The FDA has indicated that Mezzion's nonclinical data and prior safety experience with udenafil provide a reasonable foundation for clinical development. — FDA alignment reduces regulatory risk for the upcoming clinical trials.
+0.30Continue reading
6 related stories
Search tags
Udenafil showed a statistically significant reduction in a preclinical measure of cardiac hypertrophy, addressing common cardiovascular complications of ADPKD. — Additional therapeutic benefits increase the drug's competitive advantage and potential market size.
+0.20Which stocks this story touches
The company reported positive in vivo results for udenafil in treating ADPKD, supporting clinical evaluation.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
4d ago
